Tag: CellAct

August 15, 2017 Off

CellAct, Mundipharma in $250M cancer drug deal

By Dino Mustafić

CellAct Pharma, a virtual German company, has signed a more than $250 million deal with Mundipharma for further development and commercialization of CAP7.1, a prodrug etoposide that has shown efficacy in phase 2 studies in patients with biliary tract cancers.